Who Buys Axitinib from India — 77 Importers Behind a $93.6K Market

The importers of Axitinib from India can be categorized into several segments:

1. Distributors: Entities like ATLAS TRADING COMPANY and MIDAN PHARMA SCIENTIFIC BUREAU in Iraq fall into this category. They typically purchase Axitinib in bulk to supply to local pharmacies, hospitals, and clinics. Their buying behavior often involves large, periodic orders aligned with market demand and inventory cycles.

2. Re-exporters: Companies such as ZMC EXPRESS CARGO FZCO and ARROW GENERAL TRADING FZE in the United Arab Emirates serve as intermediaries, importing Axitinib for redistribution to other markets. Their order patterns are influenced by the demands of their client base across various regions, leading to variable order sizes and frequencies.

3. Hospital Groups and Retail Chains: Entities like SKIN LINE LOGISTIC in Iraq may represent hospital groups or retail chains that procure Axitinib directly for patient treatment. Their purchasing behavior is typically characterized by consistent, smaller orders to maintain adequate stock levels for ongoing patient care.

4. Government Procurement: While not explicitly listed among the top buyers, government agencies or organizations like UNICEF and the Global Fund often engage in tender-based purchasing. They procure large quantities through formal bidding processes to supply public healthcare facilities, with order patterns dictated by budget cycles and public health needs.

For the top five importing countries of Axitinib from India, the import regulations are as follows:

The demand for Axitinib in importing countries is primarily driven by the prevalence of renal cell carcinoma (RCC), for which Axitinib is a standard treatment. According to the World Health Organization (WHO), the global incidence of kidney cancer has been rising, with significant cases reported in countries like Brazil and Mexico. Government healthcare programs aiming to expand universal health coverage have prioritized the inclusion of essential oncology drugs, including Axitinib, to improve patient outcomes.

Additionally, the inclusion of Axitinib in the WHO Essential Medicines List has facilitated its procurement through international and national tender-based purchasing mechanisms. This has enabled countries to acquire Axitinib at negotiated prices, ensuring broader access. The presence of 77 buyers across 28 countries, as per TransData Nexus data, indicates a diversified and expanding market for Axitinib, presenting opportunities for suppliers to meet the growing global demand.

The importers of Axitinib from India can be categorized into several segments:

1. Distributors: Entities like ATLAS TRADING COMPANY and MIDAN PHARMA SCIENTIFIC BUREAU in Iraq fall into this category. They typically purchase Axitinib in bulk to supply to local pharmacies, hospitals, and clinics. Their buying behavior often involves large, periodic orders aligned with market demand and inventory cycles.

2. Re-exporters: Companies such as ZMC EXPRESS CARGO FZCO and ARROW GENERAL TRADING FZE in the United Arab Emirates serve as intermediaries, importing Axitinib for redistribution to other markets. Their order patterns are influenced by the demands of their client base across various regions, leading to variable order sizes and frequencies.

3. Hospital Groups and Retail Chains: Entities like SKIN LINE LOGISTIC in Iraq may represent hospital groups or retail chains that procure Axitinib directly for patient treatment. Their purchasing behavior is typically characterized by consistent, smaller orders to maintain adequate stock levels for ongoing patient care.

4. Government Procurement: While not explicitly listed among the top buyers, government agencies or organizations like UNICEF and the Global Fund often engage in tender-based purchasing. They procure large quantities through formal bidding processes to supply public healthcare facilities, with order patterns dictated by budget cycles and public health needs.

For the top five importing countries of Axitinib from India, the import regulations are as follows:

The demand for Axitinib in importing countries is primarily driven by the prevalence of renal cell carcinoma (RCC), for which Axitinib is a standard treatment. According to the World Health Organization (WHO), the global incidence of kidney cancer has been rising, with significant cases reported in countries like Brazil and Mexico. Government healthcare programs aiming to expand universal health coverage have prioritized the inclusion of essential oncology drugs, including Axitinib, to improve patient outcomes.

Additionally, the inclusion of Axitinib in the WHO Essential Medicines List has facilitated its procurement through international and national tender-based purchasing mechanisms. This has enabled countries to acquire Axitinib at negotiated prices, ensuring broader access. The presence of 77 buyers across 28 countries, as per TransData Nexus data, indicates a diversified and expanding market for Axitinib, presenting opportunities for suppliers to meet the growing global demand.